Rhythm Pharmaceuticals (RYTM) Finished Goods (2021 - 2025)

Rhythm Pharmaceuticals (RYTM) has 5 years of Finished Goods data on file, last reported at $14.5 million in Q3 2025.

• Finished Goods for Q3 2025 came in at $14.5 million, up 80.97% year-over-year; the trailing twelve-month figure through Sep 2025 was $14.5 million (up 80.97% YoY), and the FY2024 annual result was $10.7 million, up 270.12% from the prior year.
• Finished Goods grew to $14.5 million in Q3 2025 per RYTM's latest filing, from $13.6 million in the prior quarter.
• Over five years, Finished Goods peaked at $14.5 million in Q3 2025 and troughed at $111000.0 in Q4 2021.
• A 5-year average of $5.7 million and a median of $2.9 million in 2023 frame the typical range for Finished Goods.
• The sharpest annual moves came in 2022 and 2023: Finished Goods soared 75.68% in 2022, then soared 1384.62% in 2023.
• A 5-year view of Finished Goods shows it stood at $111000.0 in 2021, then soared by 75.68% to $195000.0 in 2022, then soared by 1384.62% to $2.9 million in 2023, then surged by 270.12% to $10.7 million in 2024, then jumped by 35.71% to $14.5 million in 2025.
• Business Quant data shows RYTM's Finished Goods at $14.5 million in Q3 2025, $13.6 million in Q2 2025, and $12.6 million in Q1 2025.